Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Kalincik, Tomas; Brown, J.; Robertson, Neil; Willis, Mark; Scolding, Neil; Rice, Claire; Wilkins, Alastair; Pearson, Owen; Ziemssen, Tjalf; Hutchinson, Michael; McGuigan, Christopher; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Izquierdo, Guillermo; Lugaresi, Alessandra; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Alroughani, Raed; Pucci, Eugenio; Sola, Patrizia; Hupperts, Raymond; Lechner-Scott, Jeannette; TERZİ, MURAT; Van Pesch, Vincent; Rozsa, Csilla; Grand'Maison, Francois; BOZ, CAVİT; Granella, Franco; Slee, Mark; Spitaleri, Daniele; Olascoaga, Javier; Bergamaschi, Roberto; Verheul, Freek; Vucic, Steve; McCombe, Pamela; Hodgkinson, Suzanne; Sanchez-Menoyo, Jose; Ampapa, Radek; Simo, Magdolna; Csepany, Tunde; Ramo, Cristina; Cristiano, Edgardo; Barnett, Michael; Butzkueven, Helmut; Coles, Alasdair; Grp, MSBase

doi:10.1016/s1474-4422(17)30007-8

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Copy For Citation

Kalincik T., Brown J. W. L., Robertson N., Willis M., Scolding N., Rice C. M., ...More

LANCET NEUROLOGY, vol.16, no.4, pp.271-281, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 16 Issue: 4
Publication Date: 2017
Doi Number: 10.1016/s1474-4422(17)30007-8
Journal Name: LANCET NEUROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.271-281
Karadeniz Technical University Affiliated: Yes

Abstract

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years.